URE2-Urease

Added to your cart

URE2-Urease

Cart subtotal: £0.00

View cart (0) Checkout

#SKU URE2

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Ureases are nickel-dependent enzymes that catalyse the hydrolysis of urea into ammonia and carbon dioxide. Urease is used in liquid and powder urea laboratory reagents and biosensors. It can be used in the determination of urea in biological fluids (coupled with GLDH, in the ultraviolet method). Urease can also be used as an enzyme label in ELISA.
URE2

More information

Attributes

Description

  • Abbreviations
  • URE2
  • Lead Time
  • 8 weeks
  • Storage
  • Store desiccated at -15°C or below. Allow to come
  • Shelf Life
  • 7 years
  • Manufacturer Country
  • UK
  • Source
  • Jack bean
  • Activity
  • ≥220 Nessler U/mg material (not less than 90 Bergmeyer U/mg material)
  • EC Number
  • 3.5.1.5
  • Systematic Name
  • Urea amidohydrolase
  • Unit Definition
  • Nessler Unit That amount of enzyme causing the liberation of one micromole of ammonia per minute at 25C and pH 7.0. Bergmeyer Unit That amount of enzyme causing the hydrolysis of one micromole of urea per minute at 25C and pH 8.0.
  • Form
  • A freeze-dried material

Technical Documents

Product Specification (56.43KB)

Analytical Procedures (171.74KB)

Product Information (358.26KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox